摘要
探讨尿激酶型纤溶酶原激活物受体(UPAR)mRNA、血管内皮细胞生长因子(VEGF)和癌基因c-erbB2在肝细胞癌(HCC)的表达与其病理学特性和肿瘤转移的关系。采用原位杂交方法检测肝细胞癌UPA mRNA表达,免疫组化法检测VEGF和c-erbB2的表达。肝癌转移组的UPAR mRNA、VEGF和c-erbB2阳性表达率及表达强度均明显高于无转移组,二者相比均有显著性差异(P<0.05),但它们的表达与肝癌的大小、分化程度却无关;UPAR mRNA与VEGF及c-erbB2的表达强度均呈正相关(r=0.656、0.653,P<0.05)。UPA mRNA、VEGF和c-erbB2的表达可作为肝细胞癌的侵袭表型、判断疗效以及估计预后的重要指标。
To investigate the expression of urokinase type plasminogen activator receptor （UPAR） mRNA, VEGF and c - erbB2 and to evaluate the relationship between them and pathological properties and metastasis of hepatocellular carcinoma （ HCC ）. The expression of UPAmRNA was detected by in situ hybridization, VEGF and c - erhB2 tested by immunohistochemical assay. The expression rates of UPAR mRNA, VEGF and c - erhB2 tested by immunohistoehemical assay. The expression rates of UPAR mRNA, VEGF and c - erhB2 were obviously higher in HCC with metastasis than those in HCC without metastasis （P 〈 0. 05 ）. But their expressions were not closely related to tumor size or degree of differentiation. There was a significant relationship between UPAR mRNA, VEGF and c - erbB2 in HCC （ r = 0. 656, 0. 653, P 〈 0. 05 ）. The expression of UPAR mRNA, VEGF and c - erhB2 may be important indexes on evaluating treatment and prognosis of HCC.
出处
《临床肝胆病杂志》
CAS
2007年第1期36-38,共3页
Journal of Clinical Hepatology
基金
广西科学研究与技术开发计划资助项目(桂科基0143059)
关键词
肝细胞癌
癌基因
尿激酶受体
原位杂交
免疫组化
hepatocellular carcinoma
oncogenes
urokinase type plasminogen activator receptor
in situ hybridization
immunohistochemistry
